Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells

Fig. 3

Efficacy of tumor cell suppression through combined treatment with the c-Met inhibitor PF and rhTRAIL in DDLPS PDCs. Combination treatment with PF and rhTRAIL suppressed cell viability effectively in the DDLPS established cell lines: LPS246 (a) and LPS224 (b); and in the DDLPS PDCs: 11GS-013 (c), 11GS-079 (d), 11GS-099 (e), 11GS-106 (f), 14GS-026 (g), and 14GS-076 (h)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us